262 related articles for article (PubMed ID: 25446831)
1. Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine.
Babu TM; Levine M; Fitzgerald T; Luke C; Sangster MY; Jin H; Topham D; Katz J; Treanor J; Subbarao K
Vaccine; 2014 Nov; 32(50):6798-804. PubMed ID: 25446831
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9).
Sobhanie M; Matsuoka Y; Jegaskanda S; Fitzgerald T; Mallory R; Chen Z; Luke C; Treanor J; Subbarao K
J Infect Dis; 2016 Mar; 213(6):922-9. PubMed ID: 26655841
[TBL] [Abstract][Full Text] [Related]
3. High-Affinity H7 Head and Stalk Domain-Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza Vaccine.
Halliley JL; Khurana S; Krammer F; Fitzgerald T; Coyle EM; Chung KY; Baker SF; Yang H; Martínez-Sobrido L; Treanor JJ; Subbarao K; Golding H; Topham DJ; Sangster MY
J Infect Dis; 2015 Oct; 212(8):1270-8. PubMed ID: 25838266
[TBL] [Abstract][Full Text] [Related]
4. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults.
Talaat KR; Karron RA; Callahan KA; Luke CJ; DiLorenzo SC; Chen GL; Lamirande EW; Jin H; Coelingh KL; Murphy BR; Kemble G; Subbarao K
Vaccine; 2009 Jun; 27(28):3744-53. PubMed ID: 19464558
[TBL] [Abstract][Full Text] [Related]
5. Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes.
Jegaskanda S; Mason RD; Andrews SF; Wheatley AK; Zhang R; Reynoso GV; Ambrozak DR; Santos CP; Luke CJ; Matsuoka Y; Brenchley JM; Hickman HD; Talaat KR; Permar SR; Liao HX; Yewdell JW; Koup RA; Roederer M; McDermott AB; Subbarao K
J Virol; 2018 May; 92(9):. PubMed ID: 29444938
[TBL] [Abstract][Full Text] [Related]
6. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
7. A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response.
Talaat KR; Luke CJ; Khurana S; Manischewitz J; King LR; McMahon BA; Karron RA; Lewis KD; Qin J; Follmann DA; Golding H; Neuzil KM; Subbarao K
J Infect Dis; 2014 Jun; 209(12):1860-9. PubMed ID: 24604819
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination.
El Sahly HM; Atmar RL; Patel SM; Bellamy A; Liu L; Hong W; Zhu H; Guan Y; Keitel WA;
Vaccine; 2019 May; 37(19):2561-2568. PubMed ID: 30955980
[TBL] [Abstract][Full Text] [Related]
9. Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine.
Rudenko L; Naykhin A; Donina S; Korenkov D; Petukhova G; Isakova-Sivak I; Losev I; Stukova M; Erofeeva M; Nikiforova A; Power M; Flores J
Hum Vaccin Immunother; 2015; 11(12):2839-48. PubMed ID: 26697973
[TBL] [Abstract][Full Text] [Related]
10. A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys.
Min JY; Vogel L; Matsuoka Y; Lu B; Swayne D; Jin H; Kemble G; Subbarao K
J Virol; 2010 Nov; 84(22):11950-60. PubMed ID: 20810733
[TBL] [Abstract][Full Text] [Related]
11. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.
Jadhao SJ; Achenbach J; Swayne DE; Donis R; Cox N; Matsuoka Y
Vaccine; 2008 Mar; 26(14):1742-50. PubMed ID: 18336962
[TBL] [Abstract][Full Text] [Related]
12. Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine.
Rudenko L; Kiseleva I; Naykhin AN; Erofeeva M; Stukova M; Donina S; Petukhova G; Pisareva M; Krivitskaya V; Grudinin M; Buzitskaya Z; Isakova-Sivak I; Kuznetsova S; Larionova N; Desheva J; Dubrovina I; Nikiforova A; Victor JC; Neuzil K; Flores J; Tsvetnitsky V; Kiselev O
PLoS One; 2014; 9(2):e87962. PubMed ID: 24533064
[TBL] [Abstract][Full Text] [Related]
13. Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses.
Wu CY; Chang CY; Ma HH; Wang CW; Chen YT; Hsiao PW; Chang CC; Chan CH; Liu CC; Chen JR
Vaccine; 2014 Jul; 32(35):4485-4494. PubMed ID: 24962757
[TBL] [Abstract][Full Text] [Related]
14. Optimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses.
Zhang L; Jia N; Li J; Han Y; Cao W; Wang S; Huang Z; Lu S
Hum Vaccin Immunother; 2014; 10(7):1949-58. PubMed ID: 25424804
[TBL] [Abstract][Full Text] [Related]
15. Safety and immune responses following administration of H1N1 live attenuated influenza vaccine in Thais.
Phonrat B; Pitisuttithum P; Chamnanchanunt S; Puthavathana P; Ngaosuwankul N; Louisirirotchanakul S; Dhitavat J; Thirapakpoomanunt S; Chokevivat V; Wibulpolprasert S
Vaccine; 2013 Mar; 31(11):1503-9. PubMed ID: 23318149
[TBL] [Abstract][Full Text] [Related]
16. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine.
Couch RB; Patel SM; Wade-Bowers CL; Niño D
PLoS One; 2012; 7(12):e49704. PubMed ID: 23239968
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.
Pitisuttithum P; Boonnak K; Chamnanchanunt S; Puthavathana P; Luvira V; Lerdsamran H; Kaewkungwal J; Lawpoolsri S; Thanachartwet V; Silachamroon U; Masamae W; Schuetz A; Wirachwong P; Thirapakpoomanunt S; Rudenko L; Sparrow E; Friede M; Kieny MP
Lancet Infect Dis; 2017 Aug; 17(8):833-842. PubMed ID: 28533093
[TBL] [Abstract][Full Text] [Related]
18. H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine.
Khurana S; Coyle EM; Verma S; King LR; Manischewitz J; Crevar CJ; Carter DM; Ross TM; Golding H
Vaccine; 2014 Nov; 32(48):6421-32. PubMed ID: 25284811
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of live attenuated H7N3 and H7N7 vaccine viruses for their receptor binding preferences, immunogenicity in ferrets and cross reactivity to the novel H7N9 virus.
Xu Q; Chen Z; Cheng X; Xu L; Jin H
PLoS One; 2013; 8(10):e76884. PubMed ID: 24130801
[TBL] [Abstract][Full Text] [Related]
20. Development of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets.
Chen Z; Baz M; Lu J; Paskel M; Santos C; Subbarao K; Jin H; Matsuoka Y
J Virol; 2014 Jun; 88(12):7016-23. PubMed ID: 24719414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
